- NanoViricides' (NYSE:NNVC) has successfully completed the first safety/toxicology studies evaluating broad-spectrum drug candidate NV-HHV-101, a topical cream formulation, in mini-pigs. All dose levels were well-tolerated with no safety signals observed.
- Shingles rash will be the first targeted indication for the product.
- Shares are up 45% premarket.
NanoViricides reports positive early-stage data on broad-spectrum drug candidate; shares up 45% premarket
Recommended For You
More Trending News
About NNVC Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
NNVC | - | - |
NanoViricides, Inc. |